智慧芽：2022兒科疾病治療分析與藥物研究報告（33頁）.pdf

《智慧芽：2022兒科疾病治療分析與藥物研究報告（33頁）.pdf》由會員分享，可在線閱讀，更多相關《智慧芽：2022兒科疾病治療分析與藥物研究報告（33頁）.pdf（33頁珍藏版）》請在三個皮匠報告上搜索。

1、?https:/?https:/?02?03?01?04?05Contents?https:/?900?2016?研?務?群?群?39.2%39.2%?20.5%20.5%?17.6%17.6%?15.8%15.8%?務?2019?研?2019?0 0-1515?2497724977?17.8%17.8%?16-59?89640?64.0%?60?副?25388?18.1%?務?65?副?17603?12.6%?17.80%64%18.10%2019?0-15?16-59?60?務?務?300-400?2024?2.69?(?研)?溶?3?/?9%?研?研?60%60%?研?5%5%?17.8

2、%17.8%?2011?2011?384?384?副?副?2019?2019?872?872?10.80%10.80%?務?10.69%?39.20%20.50%17.60%15.80%?6.81%?https:/?研?1?2?研務?務?90%90%?54.46%41.44%4.10%?1 1?6.3%12.9%24.4%0.0%5.0%10.0%15.0%20.0%25.0%30.0%?1 10.1%0.1%研NMPA?研?6000?10?0.1%?0 0-1 1?1 1-2424?3 3-5 5?6 6-1414?1.84?930?5%?群?90%?1?https:/?研?研?研?研?研?

3、導?試?試?試?6000?10?告?90%?副?75%?副?3 3500500+?60+60+?誘?https:/?模?模?務?;?務?告?模?模?4?的?研?https:/?CFDA?夠?11?20032003201620162013201320112011?(CFDA)?(?3尼)?20042004?務?(2011?2020?)?的?務?20122012CFDA?夠?研?研?吐?20152015?溶?告?資?告?確?2021202120222022?務?,?12?https:/?模?務?(?ICH)?ICH?E11/S11?/M11?2014?務?夠?務?2016?研?研?務?研?研?研?

4、研?研?2017?溶?務?研?務?CDE?https:/?FDA?模?1979?FDA?1994?1997?FDA?務?6?2002?&2003?吐?PBCA?PREA?2?2007?FDA?2007?吐?2012?FDA?II?夠?夠?研?2019?FDA?2-12?12-17?FDA?夠?務?62%85%?2005?2015?600600?務?2810531522699?BPCA?PREA?BPCA?PREA2007-2020?2007-2012?2012-2020?00001747352002040602012 2013 2014 2015 2016 2017 2018 20192012

5、-2019?(?)?1979?務?2003?https:/?%?4?71116.76?4?63516.49?-?3?86813.76?2?97710.59?2?7289.70?1?1163.97?1?0563.76?E?1?0083.59?9273.30?9243.29?23?95085.19-?%?220?89048.92?副?群100?14522.18?38?2738.48?18?1174.01?9?6342.13?7?6161.69?7?0571.56?5?9801.32?5?6921.26?-?4?7201.05?418?12492.61-?1.?10?2.?10?務?務?0 0 18

6、18?20102010 20162016?務?務?https:/?研?95%?%?186?96273.11?54?60621.35?4?4831.75?4?3661.71?1?7980.70?1?0740.42?8470.33?6050.24?4420.17?2790.11?255?46299.90?%?副?群113?08146.09?31?95913.02?22?4269.14?22?2049.05?14?6535.97?13?9185.67?9?2083.75?4?4831.83?3?8871.58?3?0171.23?238?83697.34-?3.?10?4.?10?https:/?/

7、?30%13%57%?研?3030%?1313%?5757%?務?2.2?2.5%?/?/?務?務?OTCOTC?研?研?https:/?7 7?5 5?(?4 4%)?3 3%?副?30%?副?20%20%?10%10%?30%?2022?副?OS?12%?OS?65%?兒童腫瘤類型多且復雜，中美兒童抗腫瘤可用藥存在差距?務?務?務?務?D?D?Mylotarg?Inotuzumab?Daratumumab?Pembrolizumab?Blinatumomab?D?https:/?導?*?得?*?導?*?*?*?導?*MSI-H+?TMB-H?-號?*?群?-?*?B?-*?2021?9?2

8、9?5?*?2021?務?號?務?務?嗎?https:/?+?研務?研?2017-2020?2020?3.62?0.004%?3.63.6?2017-2020?(?%)?研?2019?務?RSV?CMV?+?A?腺?https:/?Spinraza?SMA?SMN1?SMN?SMN1?SMN?SMA?SMN2?SMN?SMN2?7?7?90%?研?DOI:10.1001/archneurol.2011.74.Spinraza?intrathecal injection?Spinraza?2019?2?5q?SMA?95%?SMA?SMASMA?SpinrazaSpinraza?研務?研務?SM

9、A?務?SMA?3-5?盛?SMA?Spinraza?70?模?3?2021?11?20?SMA?副?Spinraza?https:/?除助聽器或人工耳蝸外，基因療法可為先天性耳聾提供創新藥解決方案?1 1/500500?1 1/10001000?研務?2003?副?20572057?16.79?3 3?群?群?務?50%?副?GJB2GJB2?GJB2?GJB2?;?SLC26A4SLC26A4?SLC26A4?的?14%?12s?RNA?A1555G12s?RNA?A1555G?mtDNA A1555G?1993?Presant?mtDNA 12Sr RNA?1555?AG?務?https

10、:/?64%64%36%36%務?%?務?務?研?研?務?研?務?務?務?研?務?研?6?12?21?38?17?https:/?研?1?Ph3?TJ101?1?Ph3?AK0529?1.1?Ph3?群ACT001?1?Ph1?2.2/2.4?Ph2?5?Ph2?XW001?1?Ph1?群?1?Ph1?KY0467?1?Ph1?2.2?Ph1?2022?副?12?務?2022/2/24?3-18?2022/3/3?2022/3/11?2022/3/11?導?2022/3/24?3?2022/3/24?3?NTRK?2022/4/13?2022/5/7?https:/TOP?1?6.28%2?翹

11、?9?3.82%3?D誘?AD誘?3.42%4?2.72%5?2.61%6?D誘?AD誘?2.35%7資?2.25%8?務?1.94%9?1.93%10?1.79%TOP?1?歲5.74%2?D誘?歲5.27%3?歲2.90%4?歲2.81%5?群?2.72%6?群?歲2.23%7?歲2.14%8?AD誘?歲2.09%9?歲1.93%10?1.88%?2020?top102020?top10?研?https:/?+?2021?(600566)204.9?10.16?10.3?603439?46.55?6399?8.79?000915?96.99?3.046?AD誘?號?9?2020?00273

12、7?99.81?4.012?翹?4.5?2.5?600557?77.05?2.111?5?300723?67.84?1.546?4.4?000999?379.6?14.33?-?腺?002412?28.13?7888?-?(600351)43.89?1.004?4.19?2019?務?(600750)90.79?3.923?務?3.5?2020?https:/?1994?務?務?務?10?210?110?2016-2021?2019?2020?務?+?2005?副?+?2020?務?務?60.43%60.43%?28.01%28.01%?務?+?務?2g/6?務?務?24.33?務?43.89

13、?https:/?AAV?&?AAVAAV?AAV?A A V M e t aA A V M e t a?溶?AAVAAV-ieieAAVAAV-WM09WM09AAVAAV-WM01WM01?6?2021.12?/?Science?AAV?AAV?AAV?(AAV)?AAVAAV?https:/?務?務?Minoryx?Leriglitazone?X-?副?(X-ALD)?2019?A?嗎?嗎?https:/?RSV?副?9?務?ziresovir?III?RSV?群?Ziresovir?AK0529?F?8?ziresovir?研?ziresovir溶?9?模?II?RSV?1-24?II

14、I?2022?NMPA?ziresovir?NMPA?務?務?3 3?3030%?RSV?務?5555%?p0.001?5 5?7777%?p=0.006?6?研?6?9.0%vs.26.3%?p=0.02?務?ZiresovirZiresovir?https:/?patch?2.2?505b(2)?模?確?務?務?2022?務?patch?010102020303010102020303010102020303?https:/?務?務?務?試?務?務?務?務?導?30?20?10?副?導?務?https:/SOWTStrength?Weakness?/?模?研?Opportunity?OTC/?2?Threat?模?+?SWOT?